Author Correction: Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells

It just came to the author’s attention that three errors were introduced into the paper during the stage of figure preparation. Specifically, the Western blotting bands of GAPDH in Fig. 2b as well as Fig. 3b, cv PARP in HCC827/GR6 cells (Fig. 3b) and IHC staining images of EGFR and Hsp70 in group gefitinib 50 mg/kg (Fig. 5d) were found to be misplaced inadvertently. These errors were made completely by accident. Under no circumstance did the authors falsify or “make up” data in order to mislead the reviewers or readers.